Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy

• Published in: Clinical cancer research Vol. 24; no. 15; pp. 3602 - 3610
• Main Authors: Hertz, Daniel L., Kidwell, Kelley M., Vangipuram, Kiran, Li, Feng, Pai, Manjunath P., Burness, Monika, Griggs, Jennifer J., Schott, Anne F., Van Poznak, Catherine, Hayes, Daniel F., Lavoie Smith, Ellen M., Henry, N. Lynn
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research Inc 01.08.2018
• Subjects: Aged; Breast cancer; Breast Neoplasms - blood; Breast Neoplasms - complications; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cancer; Confidence intervals; Constraining; Design of experiments; Dose-Response Relationship, Drug; Experimental design; Exposure; Female; Humans; Middle Aged; Paclitaxel; Paclitaxel - adverse effects; Paclitaxel - blood; Parameters; Patients; Peripheral Nervous System Diseases - blood; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - pathology; Peripheral neuropathy; Treatment Outcome

Purpose: Paclitaxel exposure, specifically the maximum concentration (Cmax) and amount of time the concentration remains above 0.05 μmol/L (Tc>0.05), has been associated with the occurrence of paclitaxel-induced peripheral neuropathy. The objective of this study was to validate the relationship b...